New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
OptiNose, Inc. (OPTN)
Last optinose, inc. earnings: 3/5 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.optinose.com
Company Research
Source: GlobeNewswire
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society. As discussed in the publication, the inability of topical medications to reach the region of the sinus cavities is a potential reason for lack of efficacy in chronic rhinosinusitis (CRS), particularly the common type without nasal polyps. This is different from rhinitis, which is effectively treated by standard-delivery topical medication, and also different from treating nasal polyps, which can sometimes extend down into areas reached by standard-delivery nasal sprays. One purpose of endoscopic sin
Show less
Read more
Impact Snapshot
Event Time:
OPTN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPTN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPTN alerts
High impacting OptiNose, Inc. news events
Weekly update
A roundup of the hottest topics
OPTN
News
- OptiNose, Inc. (NASDAQ:OPTN) Just Reported, And Analysts Assigned A US$3.50 Price Target [Yahoo! Finance]Yahoo! Finance
- OptiNose, Inc. (NASDAQ: OPTN) had its price target lowered by analysts at Piper Sandler from $3.00 to $1.00. They now have an "overweight" rating on the stock.MarketBeat
- OptiNose, Inc. (NASDAQ: OPTN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised Guidance [Yahoo! Finance]Yahoo! Finance
- Optinose Reports Third Quarter 2024 Financial Results and Recent Operational HighlightsGlobeNewswire
OPTN
Earnings
- 8/8/24 - Beat
OPTN
Analyst Actions
- 11/13/24 - HC Wainwright
OPTN
Sec Filings
- 11/20/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SCHEDULE
- OPTN's page on the SEC website